Clinical Trial Update: Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) [Phase 4]

View source ↗

Summary

A Phase 4 correction phase study of a biosimilar erythropoietin for renal anaemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Anaemia

Drugs mentioned

• biosimilar erythropoietin

Snippet

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Conditions: Renal Anaemia | Phase 4 | Status: TERMINATED